Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who live in the community and attend appointments as outpatients, and who have a family member or close contact who can provide information about them
- People aged between 65 and 100 years old
- People who have been clinically diagnosed with Alzheimer's disease or mild cognitive impairment (MCI — early-stage memory or thinking difficulties)
- People who are able to understand and agree to take part in the study on their own behalf
- People whose score on a 15-question depression screening tool (called the GDS) is 8 or below, indicating low levels of depression
- People without significant problems with their vision or hearing
- People whose everyday functioning score (measured using a tool called the dECog, compared against a standard research database) falls within a specific range of 1.0 to 5.0 (confirm with trial site)
Who may not be able to join:
- People with a history of psychosis, including visual hallucinations (seeing things that are not there)
- People with a history of, or who have been treated for, Parkinson's disease, tremor (uncontrolled shaking), or a sleep condition called REM behaviour disorder
- People with a history of an abnormally slow heart rate or episodes of fainting
- People who have been treated for cancer in the last 5 years, not including skin cancers
- People who have had major surgery in the last year
- People currently taking anti-seizure medication for a seizure or epilepsy condition
- People currently taking antipsychotic medications for agitation or psychosis (medications for anxiety or sleep difficulties are generally acceptable — confirm with trial site)
- People currently taking a type of dementia medication called a cholinesterase inhibitor (such as donepezil, rivastigmine, or galantamine), or who have taken one in the last six months
- People who have only recently started taking donepezil (less than 2 weeks ago) and are unable to stop taking it for 14 days before joining the study
- People for whom the treating doctor and trial investigator determine that this type of medication carries more risk than benefit, based on their medical history and symptoms
- People already taking part in another study that the trial investigator believes could affect safety or the quality of data in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Donald R. Royall, MD, University of Texas
Phone: 210 567 8133
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
dTEL change
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.